Supriya Lifescience Stock Screener | Share Price & Fundamental Analysis

SUPRIYA Pharmaceuticals
Share Price NSE
₹612.20
▲ 11.20 (1.86%)
2026-04-02 00:00:00
Share Price BSE
₹612.10
▲ 9.45 (1.57%)
2026-04-02 00:00:00
Track Supriya Lifescience share price live with TickJournal's free stock screener. Analyze Supriya Lifescience share price history trends and compare 52-week high low levels. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Supriya Lifescience Market Cap ₹4,728.77 Cr.
SUPRIYA P/E Ratio (TTM) 25.62
Supriya Lifescience P/B Ratio 4.39
EPS (TTM) ₹23.35
Dividend Yield 0.17%
Debt to Equity 0.01
SUPRIYA 52 Week High ₹802.65
Supriya Lifescience 52 Week Low ₹553.35
Operating Margin 36.00%
Profit Margin 24.77%
SUPRIYA Revenue (TTM) ₹747.00
EBITDA ₹275.00
Net Income ₹185.00
Total Assets ₹1,112.00
Total Equity ₹997.00

Supriya Lifescience Share Price History - Stock Screener Chart

Screen SUPRIYA historical share price movements with interactive charts. Analyze price trends and patterns.

Supriya Lifescience Company Profile - Fundamental Screener

Screen Supriya Lifescience company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SUPRIYA shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE07RO01027

Supriya Lifescience Balance Sheet Screener

Screen SUPRIYA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Assets
Total Assets 1,112 921 820 735 446 336 253 245 241 231
Current Assets 437 398 465 498 266 196 133 120 115 129
Fixed Assets 453 310 262 190 100 99 85 91 89 76
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 33 29 25 19 31 32 24 45 51 39
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 997 815 700 616 269 149 94 55 46 42
Share Capital 16 16 16 16 15 15 15 15 15 15
Reserves & Surplus 981 799 683 600 254 134 79 40 31 26

Supriya Lifescience Income Statement Screener - Profit & Revenue Analysis

Screen Supriya Lifescience income statement and profit fundamentals. Analyze SUPRIYA quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Supriya Lifescience share price evaluation.
Item None-None 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March
Revenue 747 706 581 470 538 396 323 286 222 191 172 140
Expenses 472 436 397 332 316 218 213 213 191 166 150 121
EBITDA 275 271 184 138 222 178 110 73 31 25 22 20
Operating Profit % 36.00% 37.00% 30.00% 28.00% 40.00% 44.00% 32.00% 23.00% 10.00% 9.00% 12.00% 12.00%
Depreciation 26 20 16 12 10 7 6 5 5 5 4 3
Interest 2 2 2 3 4 4 7 10 11 12 10 7
Profit Before Tax 247 249 166 124 207 167 96 57 15 8 8 10
Tax 54 61 47 34 55 44 23 18 6 2 2 2
Net Profit 185 188 119 90 152 124 73 39 9 6 6 8
EPS 23.00 23.35 14.80 11.16 18.86 16.89 10.02 5.39 1.19 3.87 3.89 16.82

Supriya Lifescience Cash Flow Screener - Liquidity Fundamentals

Screen SUPRIYA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 165 113 64 49 76 117 49 28 27 14
Investing Activities -152 -174 -124 -60 -47 -25 5 -5 -27 -33
Financing Activities -8 -22 -10 150 -15 -29 -50 -20 -2 21
Net Cash Flow 4 -83 -70 139 15 62 4 3 -2 2

Supriya Lifescience Shareholding Pattern Screener

See Supriya Lifescience shareholding pattern with promoter, FII, and DII holdings. Check Supriya Lifescience promoter holding and ownership changes for SUPRIYA on TickJournal.
Item 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec
Promoter Holding 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30% 68.30%
FII Holding 7.19% 6.78% 5.46% 5.20% 5.36% 4.95% 6.03% 6.52%
DII Holding 4.26% 4.86% 5.22% 5.01% 5.30% 5.48% 5.45% 4.92%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 16.40% 16.39% 16.77% 16.66% 17.06% 17.19% 0.00% 16.28%
Other Holding 3.85% 3.67% 4.25% 4.83% 3.98% 4.08% 20.23% 3.98%
Shareholder Count 91,051 91,928 87,912 85,099 87,980 89,621 85,328 89,394

Supriya Lifescience Share Dividend Screener - Share Yield Analysis

Check Supriya Lifescience dividend history with payout and yield data. View Supriya Lifescience dividend details including ex-dates and amounts for SUPRIYA stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹1.00 0.17%
2024-March ₹0.80 0.11%
2023-March ₹0.60 0.18%
2022-March ₹0.60 0.32%
2021-March ₹0.54 0.11%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Supriya Lifescience Stock Index Membership

See which indices include Supriya Lifescience stock. Check SUPRIYA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Supriya Lifescience Market Events Screener - Corporate Actions

Get Supriya Lifescience corporate actions including splits, bonuses, and buybacks. Check Supriya Lifescience stock events that may affect SUPRIYA share price.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 1.00 /share -11.70%
Dividend ₹ 0.60 /share 13.53%
Dividend ₹ 0.80 /share 74.84%
Annual General Meeting NA -6.20%
Dividend ₹ 0.60 /share -0.06%
Annual General Meeting NA 11.37%
2026-02-09 2026-02-09 Quarterly Result Announcement NA 0.36%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -6.66%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -0.96%
2025-05-27 2025-05-27 Quarterly Result Announcement NA 5.82%
2025-01-24 2025-01-24 Quarterly Result Announcement NA 9.11%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -1.41%

Supriya Lifescience Competitors Screener - Peer Comparison

Screen SUPRIYA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 430,345 39.32 54,729 9.71% 10,980 56.35
Divis Laboratories 159,215 64.39 9,712 18.67% 2,191 39.57
Torrent Pharmaceuticals 144,367 64.00 11,539 6.99% 1,911 49.85
Dr Reddys Laboratories 106,975 19.68 33,741 16.73% 5,725 49.71
Lupin 106,653 22.98 22,910 13.74% 3,306 56.95
Cipla 100,349 22.17 28,410 7.12% 5,291 34.82
Zydus Life Science 90,229 18.09 23,511 18.55% 4,615 49.23
Mankind Pharma 84,163 46.25 12,744 20.90% 2,007 44.70
Aurobindo Pharma 76,329 21.80 32,346 9.43% 3,484 63.55
Alkem Laboratories 63,902 26.83 13,458 3.70% 2,216 45.83

Supriya Lifescience Company Announcements - News Screener

Screen SUPRIYA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-03-30 Closure of Trading Window -
2026-03-29 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-03-11 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-03-10 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-02-17 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-02-10 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-02-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-10 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-02-09 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-02-09 Announcement under Regulation 30 (LODR)-Change in Directorate -
2026-02-09 Financial Result Quarter Ended On December 31 2025 -
2026-02-09 Board Meeting Outcome for Outcome Of Board Meeting Held On February 09 2026 -
2026-02-04 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-02-02 Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025. -
2026-01-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-12-30 Announcement under Regulation 30 (LODR)-Credit Rating -
2025-12-28 Closure of Trading Window -
2025-11-26 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2025-11-18 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2025-11-13 Announcement under Regulation 30 (LODR)-Newspaper Publication -